|
Fuqua, S A; Oesterreich, S; Hilsenbeck, S G et al. (1994) Heat shock proteins and drug resistance. Breast Cancer Res Treat 32:67-71
|
|
Fuqua, S A; Benedix, M G; Krieg, S et al. (1994) Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells. Breast Cancer Res Treat 32:177-86
|
|
Ciocca, D R; Oesterreich, S; Chamness, G C et al. (1993) Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 85:1558-70
|
|
Oesterreich, S; Weng, C N; Qiu, M et al. (1993) The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53:4443-8
|
|
Damstrup, L; Andersen, J; Kufe, D W et al. (1992) Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol 3:71-7
|
|
McGuire, W L; Hilsenbeck, S; Clark, G M (1992) Optimal mastectomy timing. J Natl Cancer Inst 84:346-8
|
|
Ciocca, D R; Fuqua, S A; Lock-Lim, S et al. (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52:3648-54
|
|
McGuire, W L; Tandon, A K; Allred, D C et al. (1992) Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr :173-80
|
|
Sunderland, M C; McGuire, W L (1990) Prognostic indicators in invasive breast cancer. Surg Clin North Am 70:989-1004
|
|
Andersen, J; Skovbon, H; Poulsen, H S (1989) Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol 25:641-3
|
Showing the most recent 10 out of 19 publications
